このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Human Observatory Study (HOS)

2026年9月2日 更新者:William Brandenburg, MD、Longevity Metrics, Inc.

The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity

The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. This linkage creates a feedback architecture designed to improve both simultaneously.

調査の概要

詳細な説明

Existing approaches to human health prediction face a structural limitation: individual clinical studies measure biology without capturing the environment, while population epidemiology captures the environment without individual biological ground truth. The Human Observatory Study resolves this by operating at both levels simultaneously through a linked dual-layer architecture.

At the individual level, participants enrolled in the 100-Year Human Aging Study contribute comprehensive multi-system health measurements. This includes clinical, physiological, cognitive, behavioral, social, occupational, and environmental data collected at fixed and mobile clinical sites. These measurements provide the biological present timepoint that historical population data alone cannot supply.

At the population level, the Observatory continuously ingests ecological data from public and private registries across multiple input domains. This includes air quality, water and chemical contaminants, wildfire and smoke exposure, altitude and terrain, climate, satellite earth observation, occupational and industrial exposure, mortality and vital statistics, demographics and social determinants, and clinical data networks at geographic resolutions from home address to global scale and beyond. This ecological layer captures the environmental and social causal structure of health and disease continuously and does not require individual enrollment.

A foundational input domain is genealogy and family history. Health and disease run in families across generations. The Observatory is designed to build and continuously expand a linked genealogical database connecting living and historical individuals to their family health histories. Information is obtained from public genealogical records, death registries, family history self-report, and genetic data where available. The long-term vision is a genealogical infrastructure of sufficient depth and breadth to trace familial health patterns across the full recorded human family tree. Therefore connecting individual present-timepoint biology to multigenerational patterns of disease, longevity, and environmental exposure that no existing biobank or longitudinal study has attempted to capture at this scale.

The linked architecture enables a feedback loop with two outputs: population-level causal estimates that inform individual screening recommendations, and individual clinical data that give population models a present biological anchor for prospective forecasting. The degree to which each input domain, alone and in combination, predicts health, disease, and death across geographic scales from neighborhood to global and beyond is the central scientific question the Observatory is designed to answer.

The Observatory launches in Colorado, chosen as the founding site for its exceptional natural variation in altitude, wildfire smoke corridors, mining and industrial chemical geographies, and frontier-to-urban socioeconomic gradient all within a compact, well-characterized geography with established academic research infrastructure. Colorado proves the model. The architecture then replicates geographically, with each new location enriching the world model for every other. The long-term vision is global coverage and beyond. Every geography will contribute its environmental, social, and biological signal to a world model that gets more accurate with every geography studied, every participant enrolled, every dataset ingested, and every causal analysis conducted.

The Human Observatory Study is conducted across all Longevity Metrics participation pathways, current and future: the Boulder fixed laboratory; all current and future fixed clinical sites; mobile screening units including the Health Ahead Bus; and an online participation pathway through which participants enroll and contribute structured data without in-person screening. Ecological data are ingested continuously from public and private registries independent of individual enrollment. All pathways operate under a single protocol with identical procedures, data management, informed consent, and safety standards.

This study is one of four that compound into one system. The 100-Year Human Aging Study (NCT07563777) supplies the clinical data and validates what it means for health, disease, disability, and death. The Health Ahead Comparative Effectiveness Study (NCT07669168) moves the screening toward increasing automation and mobility while maintaining quality. The Longevity Metrics AI/ML Development Study (NCT pending approval) builds the models that make automation, prediction, and broad utilization possible, and returns each model's geographic residuals here. This study does with sociodemographic and environmental data what the 100-Year study does with clinical data, and defines the validated envelope within which each model's output is labeled.

研究の種類

観察的

入学 (推定)

1000000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

Participants of all ages, health statuses, and demographic backgrounds enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site, plus participants completing the online health screener. No exclusions based on health status, geographic location, language, or population group. The ecological surveillance layer requires no individual enrollment.

説明

Inclusion Criteria:

  • Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.

Exclusion Criteria:

  • Age under 18 years (current protocol; pediatric amendment planned).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Life Expectancy Estimates by Geography
時間枠:From enrollment until death, assessed periodically, up to 100 years
Continuously-updated life expectancy point estimates with credible intervals generated at individual, neighborhood, ZIP code, county, state, national, global, and beyond-earth scales using individual clinical data linked to population mortality records, environmental context, and ecological data.
From enrollment until death, assessed periodically, up to 100 years
Geographic Disease Cluster and Outbreak Detection
時間枠:From enrollment until death, assessed periodically, up to 100 years
Statistically anomalous concentrations of incident disease, mortality spikes, or shared symptom patterns at neighborhood and community resolution.
From enrollment until death, assessed periodically, up to 100 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Individual Screening Recommendation Accuracy
時間枠:From enrollment until death, assessed periodically, up to 100 years
Concordance between population-level causal estimates used to generate individualized screening recommendations and actual individual health outcomes at longitudinal follow-up, assessed periodically as outcomes accrue.
From enrollment until death, assessed periodically, up to 100 years
Causal Effect Estimates for Modifiable Exposures
時間枠:From enrollment until death, assessed periodically, up to 100 years
Estimated attributable life-years gained or lost per unit change in modifiable environmental, occupational, and social exposures.
From enrollment until death, assessed periodically, up to 100 years
Geographic Variation in Disability-Free Life Expectancy
時間枠:From enrollment until death, assessed periodically, up to 100 years
Disability-free life expectancy stratified by geography, ascertained via the functional independence and disability survey instrument used across all three associated protocols.
From enrollment until death, assessed periodically, up to 100 years
Health Equity Characterization
時間枠:From enrollment until death, assessed periodically, up to 100 years
Life expectancy gaps and chronic disease disparities stratified by geography, income, race and ethnicity, educational attainment, and rural-urban classification.
From enrollment until death, assessed periodically, up to 100 years
Human Tree of Life Growth
時間枠:From enrollment until death, assessed periodically, up to 100 years
Total participants linked to genealogical record; multigenerational depth achieved; proportion of enrolled participants with identified biological relatives in the registry; total historical individuals linked across all genealogical databases.
From enrollment until death, assessed periodically, up to 100 years
Population Biological Age Acceleration
時間枠:From enrollment until death, assessed periodically, up to 100 years
Mean difference between chronological age and biological age estimate for repeat-visit participants, stratified by geographic and demographic characteristics.
From enrollment until death, assessed periodically, up to 100 years
Multi-Domain Predictor Modeling
時間枠:From enrollment until death, assessed periodically, up to 100 years
Assessment of individual and composite clinical, biological, behavioral, environmental, social, occupational, genealogical, and geographic measurements as predictors of all-cause mortality, life expectancy, and incident serious disease at population scale; analyses evaluate which domains are independently predictive, which are redundant, and which combinations provide additive or synergistic predictive value.
From enrollment until death, assessed periodically, up to 100 years
Incident Serious Health Events and Chronic Disease
時間枠:From enrollment until death, assessed periodically, up to 100 years
New diagnosis of myocardial infarction, stroke, cancer, dementia, heart failure, atrial fibrillation, sepsis, venous thromboembolism, COPD, chronic hypoxia, major fracture, type 2 diabetes, hypertension, chronic kidney disease, metabolic syndrome, or osteoporosis ascertained via periodic follow-up contact and health data network linkage.
From enrollment until death, assessed periodically, up to 100 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:William Brandenburg, MD、Longevity Metrics

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月25日

一次修了 (推定)

2099年12月31日

研究の完了 (推定)

2099年12月31日

試験登録日

最初に提出

2026年6月9日

QC基準を満たした最初の提出物

2026年6月9日

最初の投稿 (実際)

2026年6月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月8日

QC基準を満たした最後の更新が送信されました

2026年9月2日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data are not shared. The complete participant record includes facial and voice recordings, genomic data, and neighborhood-resolution geography, and cannot be de-identified; it is never released. Identifiable data are accessed only by approved researchers working within Longevity Metrics secure facilities under data use agreements, with no data removed. Specific derived, aggregate, and statistical outputs are de-identified to HIPAA Safe Harbor standards and may be published, shared with collaborators, or contributed to open-access research databases. Models, risk estimates, and analytic findings derived from the research data may be provided to external organizations or used commercially; no participant record and no dataset containing participant data is transferred.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する